4 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 4 of 4 clinical reviews.
A clinician-facing review of lemborexant pharmacogenomics, SUNRISE trial subgroup data, and practical dose-adjustment guidance for patients of Black or African ancestry.
A clinical deep-dive into lemborexant pharmacokinetics, CYP3A4 variant prevalence, and dose-adjustment considerations specific to Hispanic / Latino patients, reviewed by the HealthRX.com medical team.
South Asian patients may respond differently to lemborexant (Dayvigo) due to CYP3A4 polymorphisms, body composition differences, and underrepresentation in key trials. This article reviews available ethnicity-stratified data, pharmacogenomic factors, and practical dosing guidance.
A clinical deep-dive into lemborexant (Dayvigo) efficacy and pharmacokinetic differences in East Asian patients, covering CYP2C19 polymorphisms, SUNRISE trial subgroup data, and practical dosing guidance.